Member Info for Eureka01

This is the sort of headline we need to see (as well as some chunky sales news!):

Upfront Diagnostics Secures $4.3 Million Funding to Commercialize Stroke Test

"Upfront Diagnostics, a pioneering medical technology company based in Cambridge, today announced it has raised $4.3 million in a funding round to accelerate the commercialization of its revolutionary stroke blood test, LVOne, in the UK and expand into new markets. The funding round was led by Phoenix Investments, with participation from Cambridge Enterprise Ventures. Also, the company received non-dilutive funding from SBRI Healthcare as part of this round."

https://upfrontdiagnostics.com/upfront-diagnostics-secures-4-3-million-funding-to-commercialize-stroke-test/

7.8 million shares bought, 2,8 million shares sold. It seems there are many taking advantage of the low sp to get in today. 🙂

I did message the company spokesperson again to vent shareholders' frustrations at the continuing delays on just about everything that been expected by now. The response: "The Company are equally frustrated with the ongoing delays."

I suppose the difference is that while the board continue to draw their generous monthly salaries we, the share holders, are feeling the pain!

In spite of all the doom and gloom, the company is busy. Four days ago in the Middle East, tomorrow exhibiting at POCT Innovators Clinical Innovation EXPO in Nottingham.

https://www.linkedin.com/company/genedrive-plc/posts/?feedView=all

comment from dr mark hudson-pea****, chair of mantara health:

"this is vital work, as we raise awareness of the importance of pgx testing in patients, to make sure they are being treated optimally based on their specific genetic variants that impact how drugs work with them...or not, as the case might be! with clopidogrel failing to work as intended in 32% of the uk population (unless you happen to be british south asian, when it fails to work in 57%), patients deserve to know that what they are being treated with, actually works to help prevent another tia/stroke/mi or worse! fantastic work."

https://www.linkedin.com/company/genedrive-plc/posts/?feedview=all

TommyD25, joined in the last few days. He has posted on a number of stocks. Every one of his posts have been negative. Sounds like a paid deramper or an embittered ex shareholder.

The key words: "This is fantastic example of pharmacogenomics research in action, which has the potential to change clinical practice in cardiology clinics, wards and hospitals."

My post FROM yesterday could now read: "The same could equally apply to GDR's tests and IMO could just as well read: "GDR's point-of-care testing (POCT) is poised to play a transformative role in NICUs, stroke units AND CARDIOLOGY UNITS by enabling faster, more targeted treatment decisions. But for these tools to succeed in real-world settings — and in the market — GDR's POC tests must deliver actionable results quickly and cost-effectively, while fitting into existing clinical workflows."

Point of Care testing is becoming the way forward in many settings. This one refers to antimicrobial testing:

"Point-of-care testing (POCT) is poised to play a transformative role in antimicrobial stewardship by enabling faster, more targeted treatment decisions. But for these tools to succeed in real-world settings — and in the market — POC tests must deliver actionable results quickly and cost-effectively, while fitting into existing clinical workflows."

https://www.360dx.com/events

The same could equally apply to GDR's tests and IMO could just as well read: "GDR's point-of-care testing (POCT) is poised to play a transformative role in NICUs and stroke units by enabling faster, more targeted treatment decisions. But for these tools to succeed in real-world settings — and in the market — GDR's POC tests must deliver actionable results quickly and cost-effectively, while fitting into existing clinical workflows." 🙂

Fwiw, I did email the company spokesperson re delayed news on a number of news items due by now: specialist commissioning for MT-RNR1, discussions with the FDA on MT-RNR1, the pilot programme for Cyp2C19-ID Kit etc. The response: "The Company are aware of shareholder sentiment but are not in control of timelines." So none the wiser!

The show goes on:

✈️ "Tomorrow, we are exhibiting at the 5th POCT Advances Conference!

Visit us on Stand 7 to see our innovative POCT offering and learn how we are transforming patient outcomes through rapid pharmacogenetics.

Catch Dr John McDermott at 11:15 for his session on Transforming Personalized Medicine in POCT: precision testing for sepsis-related hearing loss and stroke prevention."

hashtag#GDR hashtag#POCT hashtag#pointofcare hashtag#pharmacogenomics hashtag#pharmacogenetics hashtag#diagnostics hashtag#genetics hashtag#innovation

On the subject of funding, I wonder if GDR has applied for any grant from Horizon, the EU's flagship science research programme. An AI response re eligibility: "Yes, Genedrive is eligible for Horizon Europe funding. As a company, Genedrive can participate in Horizon Europe projects, potentially receiving funding for research and innovation activities, according to the Innovate UK Business Connect. The key is that Genedrive must have the operational and financial capacity to carry out the proposed research, according to the European Research Executive Agency." Around 3000 grants amounting to some £500 million have been awarded to UK companies since re-entry into the programme

https://www.theguardian.com/science/2025/may/05/british-scientists-eu-horizon-research-funding-programme

"This used to trade over 100p+ a share. It can certainly get back there I feel with the expansion and moves coming." The sp was last 100p in March 2021. Unfortunately B_Positive has overlooked two things:

1) The sp was riding high on covid testing hopes which never materialised.

2) The increase in the number of shares in issue. Since March 2021 the shares in issue have increased tenfold, from 63 million to 624 million through placings, open offers and the Riverfort deal.

B_Positive, You've posted that many times. It's not huge and it's not big news IMO. Companies are not likely to give hints via Linkedin in the way you are suggesting. The company would have to release an RNS if it was price sensitive news. I suggest you take Gloria's advice and stop the persistent ramping.

B_Positive, I'm flattered that you keep on copying and pasting my posts but it would be a courtesy to acknowledge. Thanks.

*Linkedin

Fwiw I noticed a flurry of buying came in after the post was put on X. 🙂

Https://www.linkedin.com/company/genedrive-plc/posts/?feedView=all

Now that we are near the end of the month I thought it would be useful to show the sources of news which has been highlighted as due soon. Of course there may be delays but this is what the company has previously announced:

1) Specialist commissioning for MT-RNR1, due by the end of the month.

"We continue to pursue all avenues to ensure we achieve specialist commissioning before the current timescale of April 2025. In line with specialist commissioning being devolved to the Integrated Care Boards. (Interims 2024)

"Will specialist commissioning happen by April 2025?" "We remain confident of that." (Gino answering a question in the IMC December 2024)

2)Five new NICUs, taking up MT-RNR1 from May.

"PALOH-UK commenced in November 2024 and has a maximum duration of 18 months, with sites phased into two groups: Group 1, consisting of the nine sites currently using the test and Group 2, the remaining five sites, with phased go-live from May 25" (Interims March 2025)

3)Possible update on discussions with the FDA re MT-RNR1.

"We remain on track for design and initiation of required studies and are in discussions with FDA under the Breakthrough Device Program relating to these." (Final results November 2024)

4)Stroke pilot, due to complete soon.

"genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that a key milestone has been met in The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") programme for its CYP2C19-ID kit. The programme has now passed the patient numbers required for a subsequent submission for an in vitro diagnostics CE certification ("CE-IVD"), which is still anticipated in early 2025." (RNS May 2024)

5)CE-IVD for the stroke test, following the pilot programme, due soon.

"genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that a key milestone has been met in The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") programme for its CYP2C19-ID kit. The programme has now passed the patient numbers required for a subsequent submission for an in vitro diagnostics CE certification ("CE-IVD"), which is still anticipated in early 2025." (RNS May 2024)

6)Possible £200,000 unpaid tax credit

"The tax credit for the year was £0.7m (2023: £0.8m)....The £0.7m is a receivable on the balance sheet at the year end." (Final results Nov 2024) Only £500k received so far, so £200k still due.

Just a reminder that if we do get into the US market, the potential is huge. According to the Genomadix tweet whose link I posted earlier approximately 30% of Americans carry a #CYP2C19 LOF allele—reducing Clopidogrel's effectiveness.

Genomadix then have a quick poll: "If rapid CYP2C19 genotyping were available at your hospital, how likely would you be to use it?". 4 options: Very likely, somewhat likely, not likely, want to learn more. The results (so far)? 100% have voted "very likely".🙂

)

Another point to remember is that Genedrive is already in collaboration with an as yet unnamed American partner. The deal was struck exactly a year ago:

"Genedrive PLC on Wednesday said it has entered into a clinical trial agreement to support clinical studies to progress the regulatory approval of its MT-RNR1 product. The Manchester, England-based molecular diagnostics company said the deal is with a "leading multi-state physician organisation" based in the US, but did not disclose its name. The partnership will support clinical studies required for engagement with the US Food & Drug Administration." Chief Executive Officer James Cheek said: "I am delighted with this agreement to progress our aim of introduction of our MT-RNR1 point of care pharmacogenetic test to the US. The US is a particularly attractive market for this unique test, given the potential to save hundreds of individuals from life-long deafness and reduce litigation costs relating to the unwanted side effects from antibiotic use on those carrying the gene variant. Additionally, the US market is potentially the most attractive market given its size, birth rates, use of diagnostic testing and reimbursement structure."

https://www.morningstar.co.uk/uk/news/AN_1713976015786175700/genedrive-enters-clinical-trial-deal-in-us-for-mt-rnr1-us-approval.aspx